Werewolf Therapeutics to acquire Ambros Therapeutics in $500 million all-stock deal

Werewolf Therapeutics agreed to acquire Ambros Therapeutics in an all-stock merger, with the combined company operating as Ambros Therapeutics and trading on Nasdaq under ticker symbol AMBX. Ambros is a clinical-stage biopharmaceutical company developing neridronate, a bisphosphonate therapy for Complex Regional Pain Syndrome Type 1. The companies secured $150 million in concurrent private placement funding from investors including RA Capital Management and Janus Henderson Investors. Ambros expects the combined company to be fully funded through Phase 3 CRPS-RISE trial topline results anticipated in 2028 and potential FDA drug application submission, with cash runway into the first half of 2029.